In Brief: Kensey Nash
This article was originally published in The Gray Sheet
Kensey Nash: Relaunches 8F Angio-Seal in the European marketplace following a lapse of availability for several months "due to the interruption of production caused by damage from a roof collapse sustained at Kensey Nash's facility during a January snowstorm," the firm says. Angio-Seal, which is designed to seal arterial punctures following cardiac catheterization procedures, gained the CE Mark in September 1995. Kensey Nash received an FDA approvable letter for the device in July 1995...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.